Trial
NCT00637390
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Ovarian Cancer
Intervention
Alemtuzumab
Why stopped
Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-02